Literature DB >> 18984832

Possible pathogenic link between migraine and urotensin-II.

Ugur Bicak1, Hamza Karabiber, Halil I Ozerol, Mehmet Aslan, Atilla Ilhan, Cengiz Yakinci.   

Abstract

Our aim was to determine the levels of human urotensin-II (hU-II) in the plasma of migraine patients and controls, to ascertain if there were a difference in the pathogenesis of migraine. A total of 27 patients who suffer from migraines and 27 controls were included in the study. Venous blood samples were drawn twice both from migraine patients and controls to measure hU-II plasma levels. The average levels of hU-II during migraine episode, between episodes, and controls were found to be 0.483, 0.493, and 0.737 pg/mL, respectively. The levels of hU-II in the controls were higher significantly. When comparisons were made according to sex, age groups, and types and durations of migraine, there was no significant difference in the levels of hU-II in the patients. The low levels of hU-II in the plasma of migraine patients compared with controls may be an indicator of its role in the pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18984832     DOI: 10.1177/0883073808318052

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Lack of association between urotensin-II (UTS2) gene polymorphisms (Thr21Met and Ser89Asn) and migraine.

Authors:  Betül Ozan; Seniz Demiryürek; Muhammad Safdar; Yusuf Inanc; Abdullah Tuncay Demiryürek
Journal:  Bosn J Basic Med Sci       Date:  2017-08-20       Impact factor: 3.363

2.  The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.

Authors:  Ozan Balakan; Mehmet Emin Kalender; Ali Suner; Beyhan Cengiz; Serdar Oztuzcu; Recep Bayraktar; Ersin Borazan; Taner Babacan; Celaletdin Camci
Journal:  Med Sci Monit       Date:  2014-08-12

3.  Oxidative/antioxidative status, lymphocyte DNA damage, and urotensin-2 receptor level in patients with migraine attacks.

Authors:  Mehmet Yigit; Ozgur Sogut; Özlem Tataroglu; Adnan Yamanoglu; Eda Yigit; Eray Metin Güler; Omer Faruk Ozer; Abdurrahim Kocyigit
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-24       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.